Tag: intensive care unit (ICU)

Jr NTR’s cousin Taraka Ratna collapses at a rally after heart attack, rushed to hospital

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Actor-turned-politician Nandamuri Taraka Ratna collapsed at a rally on Friday following a heart attack. The 39-year-old is part of a political rally in Chittoor. Ratna was rushed to a hospital where he received medical aid. His uncle and Tollywood star Balakrishna said that his vitals were normal.

“All his parameters read okay, they have given first aid and taken care of him as well as they can. There is nothing to worry about. The doctors have also suggested us to take him to Bengaluru. He had a heart attack and his valves are blocked,” Balakrishna told the Times of India.

Ratna was part of the Telugu Desam Party’s Yuvagalam’ Padayatra. The rally was led by ex-chief minister Nara Chandrababu Naidu’s son Nara Lokesh, who is Ratna’s cousin. At the roadshow, Ratna suffered a heart attack. Ratna and Lokesh had attended a puja at the  Lakshmipuram Sri Varadaraja Swamy Temple before heading to a mosque to offer prayers. While exiting the mosque, Ratna collapsed.

ALSO READ: BJP releases candidate list for Tripura Assembly polls, CM Manik Saha to contest from Town Bordowali

He was moved to the nearby KC Hospital in Kuppam, before being stabilised and taken to the PES Medical College in Bengaluru. The heart attack was reportedly caused by a blockage of arteries around his heart, with 90 percent of his left valve being blocked. He underwent an angiogram and had a stent put in his heart valve, reported Times of India.

His cousin, actor and leader of the Jana Sena Party, Pawan Kalyan wished him a speedy recovery. Jr NTR, another cousin of Ratna, reportedly also made inquiries about Ratna’s health and condition.

The actor made his debut in the 2002 Telugu film Okato Number Kurradu and worked in movies like Taarak, Bhadri Ramudu, and Manamantha. He will be next seen in Thugs of Malgudi.

ALSO READ: Chaos at universities as student unions attempt to screen BBC documentary on PM Modi

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Mulayam Singh Yadav ‘quite critical’, says hospital

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Samajwadi Party founder Mulayam Singh Yadav continues to be critical and on lifesaving drugs in the Intensive Care Unit (ICU), Medanta hospital in Gurugram said on Sunday.

“Mulayam Singh Yadav ji’s condition is quite critical today and he is on life saving drugs. He is being treated in the ICU of Medanta Hospital, Gurugram, by a comprehensive team of specialists,” the hospital said in a health bulletin.

Yadav, 82, has been under treatment at the hospital since August 22 and was shifted to the ICU on October 2.

Following the development, Prime Minister Narendra Modi and Uttar Chief Minister Yogi Adityanathspoke with Akhilesh Yadav on Sunday to enquire about his father Mulayam Singh’s health. During the interaction, Modi assured Yadav that he will extend any possible help and assistance, PTI quoted sources as saying.

Adityanath also called doctors at the hospital and asked them to provide the best treatment to the SP patriarch, according to the information provided by the Uttar Pradesh government.

Defence Minister Rajnath Singh also informed about his conversation with Akhilesh Yadav and tweeted: “On getting information about the ill health of former Uttar Pradesh chief minister Mulayam Singh Yadav, I talked to his son Akhilesh Yadav over the phone and enquired about his well-being. I pray to god that he gets well soon.

(This is a developing story. Keep checking back for updates)

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

UK study finds arthritis drugs offer life-saving treatment for COVID-19

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Treating critically ill COVID-19 patients with drugs typically used for arthritis may significantly improve survival, a landmark UK study has found. The findings come from a trial which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).

Patients across the UK who are admitted to ICU are now set to receive the treatments using the drugs tocilizumab and sarilumab, which can reduce the time spent in hospital by up to 10 days, according to the findings of the study which were revealed this week. Results from the government-funded REMAP-CAP clinical trial showed tocilizumab and sarilumab reduced the relative risk of death by 24 percent, when administered to patients within 24 hours of entering intensive care, the Department of Health and Social Care (DHSC) said.

Patients receiving these drugs, typically used to treat rheumatoid arthritis, left intensive care between seven to 10 days earlier on average. The rollout of these treatments could therefore contribute significantly towards reducing pressures on hospitals over the coming weeks and months, it said. Updated guidance issued on Friday by the government and the National Health Service (NHS) to trusts across the UK, encourage them to use tocilizumab in their treatment of COVID-19 patients who are admitted to intensive care units, effective immediately.

The results are yet another landmark development in finding a way out of this pandemic and, when added to the armoury of vaccines and treatments already being rolled out, will play a significant role in defeating this virus, said UK Health Secretary Matt Hancock. We have worked quickly to ensure this treatment is available to NHS patients without delay, meaning hundreds of lives will be saved. I am hugely proud of the significant role our NHS and its patients have played in this international trial, and grateful to the outstanding scientists and clinicians behind REMAP-CAP [trial] who have brought this treatment to our patients, he said.

The UK government said supplies of tocilizumab are already available in hospitals across the UK and clinicians will be able to treat all those admitted to intensive care units, potentially saving hundreds of lives. The department is working closely with Roche, who manufacture tocilizumab, to ensure treatments continue to be available to UK patients. This is a significant step forward for increasing survival of patients in intensive care with COVID-19. The data shows that tocilizumab, and likely sarilumab, speed up and improve the odds of recovery in intensive care, which is crucial for helping to relieve pressure on intensive care and hospitals and saving lives, said England’s Deputy Chief Medical Officer Professor Jonathan Van-Tam.

Also Read: UK imposes mandatory COVID-19 tests for international travellers

Initial findings reported in November 2020 showed that tocilizumab, a drug used to treat arthritis, was likely to improve outcomes among critically ill COVID-19 patients. But the impact on patient survival and length of time on organ support in ICU was not clear at that time. Now, the latest analysis shows that tocilizumab and a second drug called sarilumab both types of immune modulators called IL-6 receptor antagonists have a significant impact on patient survival, reducing mortality by 8.5 per cent.

Furthermore, the treatment also improved recovery so that on average patients were able to be discharged from the ICU about a week earlier. This is a significant finding which could have immediate implications for the sickest patients with Covid-19, said Professor Anthony Gordon, Chair in Anaesthesia and Critical Care at Imperial College London and a Consultant in Intensive Care Medicine at Imperial College Healthcare Trust, involved in the trial.

We found that among critically ill adult patients those receiving breathing support in intensive care treatment with these drugs can improve their chances of survival and recovery. At a time when hospitalisations and deaths from Covid-19 are soaring in the UK, it’s crucial we continue to identify effective treatments which can help to turn the tide against this disease, he said.

Tocilizumab and sarilumab are immunosuppressive drugs used to treat rheumatoid arthritis. They were two of several immune modulation treatments included in the REMAP-CAP trial.

In June last year, the UK government approved dexamethasone as the world’s first treatment proven to reduce mortality for COVID-19. The REMAP-CAP trial found that the rate of death for those in intensive care units on corticosteroids, such as dexamethasone, and respiratory support alone was 35 per cent, which was reduced to 28 percent when tocilizumab was also administered.

The updated study results show patients receiving tocilizumab and sarilumab were more likely to improve (measured by a combination of reduced time on organ support, such as a ventilator, in the ICU and surviving the hospital admission) compared to patients who received no immune modulator.

Click here: For the latest news and updates on COVID-19

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Most lungs recover well after COVID-19, says study

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Lung tissue of patients who suffer severely from COVID-19 shows good recovery in most cases, according to a study. The researchers at the Radbound University in the Netherlands found that the group which was referred by a GP did not recover as well as patients who were admitted to the hospital’s Intensive Care Unit (ICU).

The study, published in the journal Clinical Infectious Diseases, included 124 patients who had recovered from acute COVID-19 infections. The patients were examined by CT scan and a lung functional test. After three months, the researchers took stock, which revealed that the patients’ lung tissue is recovering well.

Residual damage in the lung tissue was generally limited, and was most often seen in patients who were treated in the ICU, they said. According to the study, the most common complaints after three months are fatigue, shortness of breath and chest pains.

”The patterns we see in these patients show similarities with recovery after acute pneumonia or acute respiratory distress syndrome (ARDS), in which fluid accumulates in the lungs,” pulmonologist Bram van den Borst said. Recovery from these conditions also generally takes a long time. It is encouraging to see that lungs after COVID-19 infections exhibit this level of recovery,” van den Borst said in a statement.

In the study, the patients were divided into three categories: a group who were admitted to the ICU, patients who were admitted to a nursing ward in the hospital, and those who could stay home but experienced persisting symptoms that eventually warranted a referral from their GP. The study assessed how patients fared after three months, and revealed that the patients who were referred to the aftercare clinic by their GP showed the worst recovery in the following period, the researchers said.

Also Read: When and which COVID-19 vaccines are likely to be available in Asia

This latter group of patients was referred because of their persisting symptoms, they said. ”However, it does seem that there is a clear subgroup of patients who initially experienced mild COVID-19 symptoms and later kept experiencing persistent long-term complaints and limitations,” van den Borst explained.

”What is striking is that we barely found any anomalies in the lungs of these patients. Considering the variety and seriousness of the complaints and the plausible size of this subgroup, there is an urgent need for further research into explanations and treatment options,” he said.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Roundup of latest scientific studies on COVID-19: Survivors may have long lasting immunity

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Immune protection against severe reinfection appears lasting

Regardless of their detectable antibody levels, most COVID-19 survivors are likely to have lasting protection against severe COVID-19 if they become reinfected, thanks to other components of the body’s immune response that remember the new coronavirus in different ways, researchers say.

In a study of 185 patients, including 41 who had been infected more than six months earlier, scientists at La Jolla Institute for Immunology in California found that multiple branches of the immune system – not just antibodies – recognized the novel coronavirus for at least eight months. For example, so-called memory B cells that could recognize the virus and produce antibodies to fight it were more abundant six months after infection than at one month, they reported in a paper posted on Monday on bioRxiv ahead of peer review. The new findings ”suggest that the immune system can remember the virus for years, and most people may be protected from severe COVID-19 for a substantial time,” said study leaders Shane Crotty and Alessandro Sette.

Final data from Pfizer vaccine trial shows 95% efficacy

Final results from Pfizer Inc’s pivotal COVID-19 vaccine trial show it had a 95% success rate – even higher than an earlier analysis – and two months of follow-up data without serious side effects, the company said on Wednesday. In the study involving about 43,000 volunteers, 162 of the 170 who contracted COVID-19 had received a placebo, not the vaccine. Of the 10 participants who had severe COVID-19, only one had received the vaccine.

The final analysis of the trial’s data comes a week after interim results showed the vaccine was more than 90% effective. Moderna Inc on Monday released preliminary data for its vaccine, showing 94.5% effectiveness. Pfizer said the efficacy of its two-dose vaccine, developed with German partner BioNTech SE, was consistent across different age and ethnic groups. Efficacy in adults over age 65 was over 94%. Pfizer said it expects to make up to 50 million vaccine doses this year – enough to inoculate 25 million people – and up to 1.3 billion doses in 2021.

Respiratory muscle damage linked to severe COVID-19

Critically ill COVID-19 patients develop virus-induced damage of respiratory muscles, scientists at Amsterdam UMC in The Netherlands reported on Monday in JAMA Internal Medicine. They performed autopsy studies of the diaphragm, the main respiratory muscle, in 26 COVID-19 patients who died in the intensive care unit (ICU) and 8 ICU patients who died without COVID-19. In every one, the diaphragm muscle cell membranes contained a protein called ACE2, which the new coronavirus uses as an entryway into cells.

The researchers found genetic evidence of the virus in diaphragm muscle cells in some of those who died from COVID-19, and microscopy analyses showed much more connective tissue scarring (fibrosis) in COVID-19 patients’ diaphragms, indicating damage, study coauthor Coen Ottenheijm told Reuters. He said the diaphragm damage may help explain why it is often difficult for COVID-19 patients to breathe on their own again after they have been on mechanical ventilators in the ICU. It may also explain the persistent shortness of breath in patients recovering from COVID-19.

Cardiac arrest survival is down during the pandemic

US data from early this year suggest the pandemic has led to decreased survival rates after ”out-of-hospital” cardiac arrest. Based on nationwide data, the proportion of patients whose hearts could be restarted was 21% lower in March-April 2020 than in the same period in 2019, researchers reported on Saturday at the annual American Heart Association meeting, held virtually this year, and in JAMA Cardiology. The proportion of patients who survived to be discharged from hospitals was also lower in 2020, at 6.6%, versus 9.8% in 2019.

Also Read: COVID-19 testing allow us to gather safely for the holidays? Check out what global health care experts have to say.

Survival rates after out-of-hospital cardiac arrest had nearly doubled in the last 20 years, and ”we want to make sure we don’t lose those gains,” said coauthor Dr. Paul Chan of St. Luke’s Mid-America Heart Institute in Missouri. Dr. Clifton Callaway of the University of Pittsburgh, who viewed the presentation but was not involved in the study, said other viewers noted it is more difficult for paramedics to work wearing full personal protective gear as it takes time to put on and can impede emergency care. Furthermore, some patients may have delayed calling for help over concerns of becoming infected with the coronavirus. And some may have also had COVID-19, making their medical condition more severe.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Critical care beds full as COVID-19 cases rise in Mumbai; BMC ramping up capacity

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Almost all intensive care unit (ICU) beds available for COVID-19 treatment in Mumbai are occupied, indicating the severe dearth of critical care as cases rise in the city. As of May 25, of the 644 COVID care ICU beds available in the city, 96 percent were already occupied.

Almost 66 percent of 359 critical care beds with ventilators were taken and 63 percent of the 4,116 beds with oxygen support were occupied.

Total 32,791 confirmed COVID-19 cases have been reported in the city, of which 22,912 are active cases. The virus has claimed 1,065 lives so far.

According to BMC, about 5 percent of COVID-19 patients need critical care in the city and the civic body is ramping up its bed capacity, while also working towards catching the disease early.

With its containment plan, Mumbai expects to have 27,000 active cases by the end of May, contrary to the earlier projection of nearly 50,000 cases.

However, even at the current rate, Mumbai will require nearly 1,600-1,700 ICU beds.

As part of its order for private hospitals to reserve 80 percent beds to be regulated by BMC, the governing body gets access to nearly 650 ICU beds in private hospitals.

Also Read: COVID-19 Mumbai report: Patients wait for days in hospital compounds for treatment as beds completely occupied

BMC has also been setting up jumbo facilities that will add 600 ICU beds. BMC Chief Iqbal Singh Chahal, in a press briefing said, “We have nearly 10,000 beds in DCH & DCHC now and by May 31, it will be expanded to 14,000 beds.”

To deal with the shortage of beds, the BMC has been setting up massive facilities at Bandra Kurla Complex, Dahisar, Mulund, NESCO Grounds in Goregaon and Mahalaxmi Race Course. These five facilities have added 5,400 isolation beds, 1,200 oxygen supported beds, 600 ICU beds and 180 beds with ventilator support. The NESCO facility in Goregaon is the largest so far with nearly 2,500 beds in total. In next two weeks all these facilities will be available.

To avoid situations where owing to lack of beds patients are made to run from one hospital to another, a single portal will collate data on all beds in both govt and private hospitals. A live dashboard will also update the usage and availability of beds across the city.

BMC is increasing the number of helpline numbers to cater to a larger requirement. The helpline number will also be used for checking bed availability and directing patients to hospitals that have vacant beds.

BMC Chief said the strategy now is to ‘chase the virus’ with proactive steps and this will also help reduce the mortality rate below 3 percent. “We managed to bring down Mumbai’s mortality to 3.2 percent from 7 percent in April. With specific measures mortality rate will further go down to 3 percent and below that.”

BMC is looking at expanding contact-tracing, early detection of co-morbid & high-risk persons, detecting low oxygen saturation in elderly & co-morbid patients and adding capacities for dialysis.

Talking about getting more healthcare workers, Chahal said 3,700 doctors, nurses and paramedical staff have responded to the request for COVID duty, of these 570 doctors and nurses have chosen the jumbo facilities for service, said Chahal.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Coronavirus: British PM Johnson spends second night in intensive care; condition stable

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

British Prime Minister Boris Johnson was spending a second night in intensive care battling the coronavirus which has infected more than 55,000 across the country and killed nearly 6,200.

“He stayed at work for you… now pray at home for him,” The Sun tabloid splashed across its front page Wednesday while the Daily Express said: “Boris ‘will pull through’.”

Deputising for Johnson, Foreign Secretary Dominic Raab said he was “confident he’ll pull through, because if there’s one thing I know about this prime minister, he’s a fighter and he’ll be back, leading us through this crisis in short order”.

In an update Tuesday evening, the prime minister’s spokesman said his “condition is stable and he remains in intensive care for close monitoring.” He earlier said the 55-year-old Conservative leader was receiving “standard oxygen treatment and breathing without any other assistance” and had not required a ventilator.

Johnson is the most high-profile government leader to become infected with COVID-19 and messages of support flooded in from across Britain and the world.

He was admitted to intensive care on Monday evening after spending Sunday night in hospital following concerns he still had a cough and high temperature 10 days after being diagnosed with COVID-19.

His transfer to intensive care is unprecedented for a prime minister during a national emergency.

For many people, it brought home the seriousness of the disease that has so far seen 6,159 deaths in Britain, with a record 786 more reported in a daily update on Tuesday.

Despite the record daily death toll, there was more encouraging news with the number of new daily cases remaining at a roughly stable 3,643.

In a round of broadcast interviews, senior minister Michael Gove insisted the “work of government goes on”.

He later said he was now staying at home after a family member displayed mild coronavirus symptoms.

Raab chaired the daily coronavirus meeting in the prime minister’s place on Tuesday.

“There is a clear plan… the government and the cabinet are working together to implement that plan,” Johnson’s spokesman said when asked if there was a power vacuum in Britain.

The country does not have a formal constitutional role of deputy prime minister, and experts said Raab would need the support of the rest of the cabinet to make any big decisions.

The most pressing issue is a review expected next week on whether to continue the nationwide lockdown introduced on March 23 to try to stem the spread of COVID-19.

Johnson announced on March 27 that he had coronavirus and went into self-isolation in a flat above his Downing Street office.

But on Monday evening he was moved to intensive care in London’s St Thomas’ hospital after his condition worsened.

The prime minister has received messages of support from around the world, with US President Donald Trump sending best wishes to his “very good friend” while Russian leader Vladimir Putin said Johnson’s “energy, optimism and sense of humour” would see him through.

For some, Johnson’s larger-than-life personality has made his hospitalisation all the more shocking.

His biographer Andrew Gimson said Johnson always made him feel upbeat, and “now here he is the stricken one”.

“This is an enormous shock, completely unfamiliar territory for all those who know him,” he told BBC radio.

Experts said it was not uncommon for coronavirus patients to move to intensive care, but said it showed Johnson’s condition was serious.

“There is no doubt this turn of events means Boris Johnson is extremely sick,” said Derek Hill, professor of medical imaging at University College London.

The British government was criticised for initially refusing to follow other European countries in requiring people to stay home as the virus spread rapidly across the globe.

Johnson himself said in early March that he was still shaking hands with people.

Two weeks ago, he ordered a nationwide lockdown, but parliament continued to sit for several days after and Westminster became a hotspot for the virus.

Health Secretary Matt Hancock and the heir to the throne, Prince Charles, have both been infected, although they have since recovered.

Johnson, who has been prime minister only since July last year, is not known to have any underlying health issues, although he has struggled with his weight.

Johnson’s pregnant partner, Carrie Symonds, moved out of Downing Street after some staff fell ill.

But she said on Saturday she had just spent a week in bed with symptoms, although she has not been tested. (AFP)

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

COVID-19 impact: Most hospitals have inadequate personal protection equipment, says Max Healthcare

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

As the number of COVID-19 cases rise. Abhay Soi, Chairman of Max Healthcare discussing the increased load on hospitals as well as their preparedness to handle the same said, there is a short term, medium term, and a long term that is going to perhaps play out as far as the virus is concerned.

He said that there will be postponement of surgeries and medical tourism. “You are going to have postponement of elective surgeries and cancellation of international medical tourism. Essentially, we are going to have a situation where occupancies will go down to about 25-30 percent. That is because of the level of emergency admissions most hospitals have, be it government or private,” he said.

“At this point of time occupancy levels for most players have plummeted to about 40-45 percent and over the next few days I do estimate that going down to about 25-30 percent,” he said in an interview with CNBC-TV18.

However, he expects the occupancies to surge as COVID-19 cases increase. “Although business has been impacted, we have to gear up for higher level of operations. In the medium run, if the COVID-19 surge comes, we are going to have very high level of occupancies.

“And once that abates, and I hope over the short to medium run that should happen, you are going to have capacities perhaps come down for some time while COVID-19 is going out of the picture, and then suddenly surge because of a lot of the electives would form a part of the latent demand at that stage,” he added.

According to him, there is need to be infrastructure ready for COVID-19 patients. “Most of these are medical cases and so you do require a little more capacity as far as ventilators are concerned. Other than this, you need to create negative pressure rooms in ICUs. That can be done with a very small amount of tinkering as far as heating, ventilation, and air conditioning (HVAC) system and the mechanics are concerned,” he added.

However, there is a need for personal protection equipment (PPE). “We run 3500 beds, a 350 bed hospital will require about 20,000-25,000 personal protection gears in a month and that is a very large number. We will require about 2.5 lakh PPE and that is where the problem is because most players, be it the private sector or the public sector, their capacities or their stock of PPE at this stage is inadequate to vastly inadequate,” he said.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow